Skip to content

Clinical trials

Cardiomyopathy, Hypertrophic trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Cardiomyopathy, Hypertrophic Country / region: China Clear all

68 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20113
20151
20163
20174
20181
20191
20203
20214
20228
202312
202410
202510
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status22
Completed19
Recruiting12
Active, not recruiting7
Not yet recruiting5
Enrolling by invitation2
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Xijing Hospital10
China National Center for Cardiovascular Diseases9
Shandong Suncadia Medicine Co., Ltd.6
Chinese Academy of Medical Sciences, Fuwai Hospital4
Bristol-Myers Squibb3
Second Affiliated Hospital, Zhejiang University, School of Medicine3
Xiang Wei3
Beijing Institute of Heart, Lung and Blood Vessel Diseases2
Corxel Pharmaceuticals2
Cytokinetics2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Cardiomyopathy, Hypertrophic68
Cardiomyopathy, Dilated5
Arrhythmogenic Right Ventricular Dysplasia3
Cardiomyopathy, Restrictive3
Hypertrophy, Left Ventricular3
Atrial Fibrillation2
Fabry Disease2
Mitral Valve Insufficiency2
Postoperative Complications2
Amyloid Neuropathies, Familial1

Trials

Showing 51 to 68 of 68. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.